Index of drugs

Topical treatment of purulent bacterial conjunctivitis caused by moxifloxacin-sensitive strains. Official guidance on the proper use of antibacterial drugs should be taken into account.

1 ml of solution contains 5 mg of moxifloxacin hydrochloride.

Antibiotic from the fluoroquinolone group. It exerts bactericidal action due to the inhibition of DNA gyrase and topoimerase IV. Works on: Gram-positive aerobic bacteria:Corynebacterium (includingC. diphteriae), Staphylococcus aureus (sensitive to methicillin),Streptococcus pneumoniae, S. pyogenes, groupStreptococcus viridans; aerobic Gram-negative bacteria:Enterobacter cloacae, Haemophilus influenzae, Klebsiella oxytoca, Moraxella catarhalis, Serratia marcescens; anaerobic bacteria:Propionibacterium acnes; other:Chlamydia trachomatis. Strains for which acquired resistance may be a problem:Staphylococcus aureus (resistant to methicillin), coagulose negative strainsstaphylococcus (resistant to methicillin),Neisseria gonorrhoeae. Bacteria with hereditary resistance:Pseudomonas aeruginosa.

Hypersensitivity to moxifloxacin, other quinolones or any of the excipients.

If an allergic reaction occurs, the preparation should be discontinued and appropriate treatment should be given. Prolonged use of the drug may cause excessive growth of non-susceptible organisms, including fungi - if superinfection should occur, discontinue use and initiate appropriate alternative treatment. In the case of systemic administration of fluoroquinolones, tendinitis and rupture may occur, especially in elderly or concomitantly treated corticosteroids. After administration of moxifloxacin in the eye, the plasma concentration of moxifloxacin is significantly lower than after oral administration, nevertheless caution should be exercised and the first symptoms of tendonitis should be discontinued. In patients receiving quinolones systemically, cases of serious and sometimes fatal hypersensitivity reactions (anaphylactic reactions) have been reported; some occurred after the first dose of the drug; some of the reactions proceeded with cardiovascular collapse, loss of consciousness, vasomotor edema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria and pruritus. Data to determine the efficacy and safety of the preparation in the treatment of conjunctivitis in the newborn are very limited - use is not recommended. The preparation should not be used in the prophylactic or empiric treatment of gonococcal conjunctivitis, including gonococcal conjunctivitis, due to the presence of strainsNeisseria gonorrhoeae resistant to fluoroquinolones. Patients with eye infections caused byN. gonorrhoeae they should be treated properly in general. The use of the preparation is not recommended for the treatment of infectionsChlamydia trachomatis in patients less than 2 years old - no studies in these patients. Patients older than 2 years with eye infections caused byCh. trachomatis they should be treated properly in general. Newborns with neonatal conjunctivitis should be treated according to their condition, i.e. general treatment in cases caused byCh. trachomatis orN. gonorrhoeae. Patients should be instructed not to use contact lenses when they have subjective and subjective signs of bacterial infection of their eyes. The preparation should not be injected subconjunctivally or inserted directly into the anterior chamber of the eye.

The preparation can be used during pregnancy and breastfeeding.

Common: eye pain, eye irritation, dry eye, pruritus of the eye, conjunctival congestion, ocular congestion, taste disturbances. Uncommon: corneal epithelial abnormalities, punctate keratitis, keratoconjunctivitis, conjunctival haemorrhage, conjunctivitis, eye swelling, eye discomfort, blurred vision, reduced visual acuity, eyelid disease, abnormal sensation in the eye, decreased hemoglobin, headache, paresthesia, feeling of discomfort in the nose, sore throat and larynx, feeling of the presence of a foreign body (in the throat), vomiting, increased ALT activity, increased GGT activity.Not known: internal ocular inflammation, ulcerative keratitis, corneal erosions, corneal abrasions, increased intraocular pressure, corneal opacity, corneal infiltration, corneal deposits, eye allergy, keratitis, corneal edema, photophobia, corneal disease, blepharitis, swollen eyelids, increased tearing, discharge from the eye, feeling of a foreign body in the eyes, palpitations, dizziness, shortness of breath, nausea, erythema of the rash, pruritus, hypersensitivity.

Adults, adolescents and children: 1 drop 3 times daily into the conjunctival sac of the affected eye (eyes). The improvement usually takes place within 5 days, but the treatment should be continued for another 2-3 days. If there is no improvement within 5 days of treatment, the diagnosis and treatment should be verified. The duration of treatment depends on the severity of the disease and the clinical and bacteriological course of the infection. To prevent the absorption of the drug through the nasal mucosa, especially in newborns and children, it is recommended to close the nasal-lacrimal canal for 2-3 minutes after applying the drop by pressing with your fingers. No dosage adjustment is necessary in elderly patients as well as in patients with impaired hepatic and renal function. If the patient uses more than one eye medicine, each of these medicines should be given at least 5 minutes apart. Eye Ointment should be used at the end.